Język
angielski
Treść
Cardiovascular risk biomarkers help to define cardiac dysfunction, assist pharmacological therapy and select patients qualifying for cardiac device implantation and/or heart transplant. Some biomarkers are of value in detecting dilated cardiomyopathy (DCM) in Emery–Dreifuss muscular dystrophy (EDMD), a genetically transmitted deficiency of emerin (EDMD1) or lamin A/C (EDMD2). Clinical symptoms of EDMD manifest as skeletal muscle atrophy, joint contractures and dilated cardiomyopathy (DCM). The latter often remains clinically silent for a prolonged period, but finally might lead to sudden death.
